NCIt definition : A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable
fragments (scFv), one directed against the tumor-associated antigen (TAA) FLT3 tyrosine
kinase receptor (Fms-like tyrosine kinase 3; FLT3; FLT-3; CD135; fetal liver kinase-2;
FLK2), fused to one that is directed against the CD3 antigen found on T-lymphocytes,
with potential immunostimulating and antineoplastic activities. Upon administration,
emirodatamab binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and FLT3 found on
FLT3-expressing tumor cells. This activates and redirects CTLs to FLT3-expressing
tumor cells, which results in the CTL-mediated cell death of FLT3-expressing tumor
cells. FLT3, a cytokine receptor belonging to the class III tyrosine kinase receptors,
is overexpressed or mutated in most B-lineage and acute myeloid leukemias (AMLs).;
UNII : P9I9Z3MF7Z;
CAS number : 2449199-61-3; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2449199-61-3
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Semantic type(s)